1. Netherlands Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
Koninklijke DSM N.V.

Koninklijke DSM N.V.

KDSKF
Koninklijke DSM N.V.US flagOther OTC
25.30
USD
-49.70
- -
4.40BMarket Cap
Koninklijke DSM N.V.
KDSKF
(Other OTC)

Recent

price

25.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
57.49
48.45
49.84
54.65
51.88
51.45
40.85
44.29
45.23
49.38
52.86
45.51
47.26
42.1
48.48
43.62
50.04
Revenue per Share
3.45
2.01
3.15
4.86
1.62
1.52
0.78
0.45
3.52
10.07
6.1
4.27
2.91
9.67
9.79
13.29
3.12
Basic EPS, GAAP
1.94
5.04
4.19
2.45
0.27
2.03
0.9
0.88
2.99
2.52
4.6
7.8
8.61
8.22
5.54
3.26
8.62
Free Cash Flow per Basic Share
1.34
1.26
1.26
0.94
1.27
0.93
1.01
1
1.09
1.14
1.28
1.66
1.68
1.54
1.99
22.61
0.74
Dividend per Share
33.44
34.42
34.39
34.47
34
32.98
31.38
29.82
31.56
42.87
44.03
45.81
47.39
51.36
58.38
46.52
47.45
Book Value per Share
21.29
24.38
27.47
25.29
19.63
19.78
17.78
13.78
17.09
22.92
26.95
24.58
17.76
23.67
32.92
21.34
17.78
Tangible Book Value per Share
164
162
164
166
166
172
173
174
175
175
175
176
172
173
173
174
171
Basic Weighted Avg Shares
9,439
7,866
8,176
9,048
8,588
8,858
7,051
7,722
7,920
8,632
9,267
7,998
8,106
7,269
8,390
7,590
8,573
Sales/Revenue/Turnover
9.09
1.28
8.15
9.24
7.3
8.33
8.24
4.71
8.02
9.33
13.11
10.18
8.34
9.8
7.68
-5.92
10.23
Operating Margin (%)
451
656
424
502
474
539
549
742
489
502
509
632
740
681
652
636
- -
Depreciation Expense
577
317
507
814
278
271
145
88
621
1,769
1,077
758
506
1,676
1,700
2,318
534
Net Income, GAAP
24.17
19.62
24.56
18.68
17.46
17.63
17.32
23.23
16.12
15.5
16.96
18.59
17.82
20.13
20.88
- -
18.4
Effective Tax Rate (%)
6.11
4.03
6.2
9
3.24
3.06
2.06
1.14
7.84
20.49
11.62
9.48
6.24
23.06
20.26
30.54
6.23
Profit Margin (%)
1,380
2,257
3,071
3,049
1,682
1,582
744
1,501
1,883
3,204
3,739
3,061
3,177
3,700
5,570
3,162
3,177
Working Capital
1,559
2,066
1,992
2,029
1,922
1,725
1,637
2,557
2,552
2,551
2,272
2,464
3,484
2,995
2,978
2,487
3,484
LT Debt
4,695
5,011
5,577
5,974
6,042
6,096
5,936
5,631
6,180
7,065
7,815
7,835
7,487
9,397
10,845
8,923
7,487
Total Equity
9.1
1.12
6.62
8.43
6.11
6.98
5.49
3.24
5.86
7
9.91
6.27
5.12
4.79
3.83
- -
6.6
Return on Invested Capital (%)
8.33
5.01
7.09
10.51
4.43
4.45
2.85
2.44
8.47
19.41
11.35
7.94
5.17
14.72
14.12
- -
4.69
Return on Capital (%)
9.86
5.9
9.21
14.17
4.73
4.62
2.43
1.47
11.5
27.05
14.05
9.51
6.17
19.65
17.86
25.41
6.6
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'20
Sep'20
Dec'20
ST Debt
605
316
102
LT Borrowings
- -
- -
3,316
LT Finance Leases
- -
- -
168
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
172
172
Market Capitalization
20,424
23,110
23,730

Working Capital

FRC

•

in mil. unless spec.
Jun'20
Sep'20
Dec'20
Total Current Assets
5,890
6,305
5,420
Cash, Cash Equivalents & STI
1,955
1,726
914
Accounts Receivable, Net
1,643
1,393
1,391
Inventories
2,177
1,953
1,879
Total Current Liabilities
2,847
2,346
2,243
Payables & Accruals
- -
- -
- -
ST Debt
605
316
102
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.6%
3.8%
-17.72%
Free Cash Flow
25.28%
0.14%
-40.71%
Net Income, GAAP
87.18%
41.23%
36.35%
Sales/Revenue/Turnover
-0.88%
-3.36%
-9.54%
Total Cash Common Dividend
115.07%
222.33%
1,059%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
7,269
2022
- -
- -
- -
- -
8,390
2023
- -
- -
- -
- -
7,590

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
9.67
2022
- -
- -
- -
- -
9.79
2023
- -
- -
- -
- -
13.29

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
1.54
2022
- -
- -
- -
- -
1.99
2023
- -
- -
- -
- -
22.61
Similar Companies
Linde plc (LIN)
Nippon Denko Co., Ltd. (5563.T)
Zenova Group Plc (ZED.L)
Hawkins, Inc. (HWKN)
Guangzhou Jointas Chemical Co., Ltd. (002909.SZ)
Taiyo Holdings Co., Ltd. (4626.T)
Business
Koninklijke DSM N.V. (KDSKF) is a global science-based company focused on nutrition, health, and sustainable living, operating primarily in the segments of nutrition and health, animal nutrition, and materials sciences. The company develops and manufactures nutritional ingredients, medical nutrition products, early-life nutrition solutions, vitamins, enzymes, and probiotics for human and animal health; performance materials including engineering plastics, polyamides, and coatings; and sustainable biobased products such as fermented ingredients and renewable chemicals. Its offerings target consumer markets, healthcare professionals, food and beverage manufacturers, animal feed producers, and industrial clients across food, feed, pharma, and personal care industries. Headquartered in Heerlen, Netherlands, and founded in 1902 as a Dutch State Mine before evolving into a diversified nutrition and materials leader, DSM maintains extensive global operations with production facilities, R&D centers, and sales offices in over 50 countries, including major presence in Europe, North America, Asia-Pacific, and Latin America. Subsidiaries and joint ventures, such as DSM Nutritional Products and Fresenius Kabi (partnered for medical nutrition), support its integrated supply chain from innovation to commercialization. In recent developments, DSM completed its strategic separation from legacy businesses, fully demerging its engineering materials division into a standalone entity, Symphony Environmental Ltd., in 2023 to sharpen focus on nutrition and health growth areas. The company secured a major multi-year partnership with Mars, Incorporated in 2024 to co-develop sustainable pet nutrition solutions using precision fermentation technology. Additionally, DSM launched its YEASTIA™ branded yeast extract platform in late 2024, expanding savory flavor and umami ingredient offerings for clean-label food products, while raising EUR 500 million through a green bond issuance in early 2025 to fund sustainability initiatives amid expanding biobased production capacities in Asia.

Company News

APIChatGPT

  • seekingalpha.com

    DSM-Firmenich AG (DSFIY) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    DSM-Firmenich AG (KDSKF) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    DSM-Firmenich AG (DSFIY) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    DSM-Firmenich AG (KDSKF) Q3 2025 Sales Call Transcript

  • seekingalpha.com

    Artisan International Value Fund Q3 2025 Portfolio Update

  • seekingalpha.com

    DSM-Firmenich AG (DSFIY) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    DSM-Firmenich AG (KDSKF) Q1 2025 Earnings Call Transcript

  • seekingalpha.com

    DSM-Firmenich AG (KDSKF) Q3 2024 Earnings Call Transcript

  • seekingalpha.com

    DSM-Firmenich AG (KDSKF) Q2 2024 Earnings Call Transcript